Pharscin Pharma(SZ:002907)2025-06-12 08:00Group 1: Company Performance and Financials - In 2024, the company achieved a revenue of 775 million CNY, an increase of 12.04% year-on-year, driven by strong growth in traditional Chinese medicine products, with five key products growing by 21.71% [7] - The sales revenue of Ganju Bingmei tablets increased by 29.97%, while the sales revenue of Liwei Anshen capsules grew by 23.38% [7] - In Q1 2025, the company reported a revenue of 239 million CNY, a year-on-year increase of 4.62%, with a slowdown attributed to reduced market demand compared to the previous year's flu outbreak [7] - The five key traditional Chinese medicine products saw a slight revenue increase of 0.93% in Q1 2025, with Liwei Anshen capsules growing by 32.10% and Tongxie Ning granules increasing by 80.24% [7] - The overall growth of state drug collection varieties during the reporting period was 28.71%, indicating strong market access and execution capabilities [7] Group 2: Product Development and Clinical Trials - ORIC-1940 is a novel RIPK1 inhibitor, currently in clinical trials for HLH, with expectations for data from Phase Ib trials to emerge next year [3][4] - The molecule has shown good safety in preclinical studies and aims to address the limitations of existing therapies in HLH treatment [3] - The company plans to explore additional indications for ORIC-1940, including adult secondary HLH and potentially primary HLH and pediatric HLH [5] - The company is actively pursuing overseas business development opportunities for ORIC-1940, although the success of these efforts remains uncertain [5] Group 3: Market Strategy and Future Outlook - The company maintains a commitment to investing in innovative drug development, with future expenses and plans contingent on actual project conditions [5] - The Southeast Asian market is viewed as a new international market for the company, with uncertain volume growth expectations [6] - The company is focused on optimizing its product structure and has successfully established a "333" pipeline layout, with new products expected to contribute to future revenue growth [7]